Approximately 120 of the top reseachers from around the world gathered at NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia, an invitation-only meeting focused on the latest advances in hemostasis research. The workshop was held October 21-22, 2016, at Georgetown University.
Researchers presented their latest findings on topics such as gene editing and cell therapy, gene therapy clinical trials and immunology. At the forefront of their research is the goal of developing better treatments in the future for people with bleeding disorders.
During the course of the two-day conference, the attendees were able to ask questions, and provide collaborative support and guidance to assist in progressing current research.
An in-depth report detailing specific content from this workshop will be published in an upcoming feature article in NHF's award-winning magazine, HemAware.
NHF is grateful to the following companies and organizations for their support of the conference: Presenting Sponsors Genentech, Pfizer and Shire; Supporting Sponsors Bayer, Biogen, BioMarin, Grifols, Novo Nordisk, Spark Therapeutics, Sangamo BioSciences; and Sponsors Alnylam Pharmaceuticals, Dimension Therapeutics, uniQure and the World Federation of Hemophilia.
